Backgrounds/Aims: This study aimed to validate the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for pancreatic adenocarcinoma and to propose an improved staging system for this disease. Methods: Between 2000 and 2014, 1656 patients underwent surgical resection for pancreatic ductal adenocarcinoma at Asan Medical Center, Seoul, South Korea. The 1169 patients included in this study were recategorized according to the eighth edition of the AJCC staging system. Patients were also categorized according to a new staging system, based on tumor size and number of metastatic lymph nodes. Results: The seventh edition of the AJCC staging system categorized 93.7% of patients as having stage T3 tumors. Stages were distributed more evenly with the eighth edition. In the N0 group, classification according to the seventh edition showed no statistically significant differences in survival rate between patients with T1 and T2 (p=0.717) and with IA and IB (p=0.717) tumors. Survival rates classified according to the eighth edition differed significantly for all pairs of T stages (p＜0.05). With both editions, N stages showed statistically significant differences (p＜0.05). Reanalysis showed that a staging system using a tumor size ≥3 cm and ≥1 metastatic lymph nodes was more predictive of survival rates. Conclusions: Compared with the seventh edition, the eighth edition of the AJCC staging system for pancreatic adenocarcinoma showed a more even distribution in T stage but marginal differences in other stages. The proposed system, using tumor size and number of metastatic lymph nodes, was better at predicting survival. 
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with poor prognosis due to the lack of specific symptoms, late detection, and aggressive invasion. [1] [2] [3] Efforts have been made to evaluate long-term survival prognostic factors in patients with PDAC. Among the factors reported to influence survival are patient age, tumor size, pathological differentiation, and lymph node metastases. [4] [5] [6] PDAC stages are also regarded as prognostic factors and used to determine if additional adjuvant treatment is required. 2, 7 The cancer staging system of the American Joint
Committee on Cancer (AJCC) includes tumor size and extent and the presence or absence of regional lymph nodes and distant metastases. 8, 9 Stage-specific treatments have undergone developments over time. 10, 11 To apply these treatments appropriately, tumor stage should be the strongest determinant of outcome. However, when patients with PDAC were classified in accordance with the seventh T and N staging system (Table 1) , almost all patients were found to have stage T3 tumors (stages IIA and IIB), with survival rates varying in patients classified as having stage IIB tumors. Moreover, the survival rates at each stage were not evenly distributed, indicating that this staging system did not effectively reflect patient prognosis. Stage IA  T1  N0  M0  Stage IB  T2  N0  M0  Stage IIA  T3  N0  M0  Stage IIB  T1-T3  N1  M0  Stage III  Any T  T4   N2  Any N   M0  M0  Stage IV Any T Any N M1
The eighth edition of the AJCC staging system for PDAC was recently described (Table 2) . 9 Compared with the seventh edition, the eighth edition classifies patients mainly by tumor size rather than by tumor extent, similar to staging systems for other cancers of the gastrointestinal tract. The AJCC seventh edition included only two N stages, based on the presence or absence of metastatic lymph nodes. By contrast, the AJCC eighth edition includes three N stage categories, based on the number of metastatic lymph nodes. The purposes of this study were to validate the eighth AJCC T and N staging system for PDAC, to compare its predictive ability with that of the AJCC seventh edition, and to develop a staging system more effective than the eighth edition of the AJCC staging system. In addition, this study identified factors other than TNM stage that affected survival rate. 
MATERIALS AND METHODS

Statistical analysis
Univariate analysis of factors associated with overall survival was performed using the Kaplan-Meier method and compared by the log-rank test. p-values ＜0.05 were considered statistically significant. Multivariate analysis of all factors found to be significant on univariate analysis was performed using a Cox proportional hazards model.
All statistical analyses were performed using SPSS version 18.0 (IBM SPSS).
RESULTS
Demographic and clinicopathological factors
The demographic and clinicopathological factors of the 1656 patients are shown in Table 3 When analyzed by N stage according to the seventh staging system, the median survival periods of patients classified as N0 and N1 were 31.5 and 18.1 months, respectively, a difference that was statistically significant (p＜0.001). The 5 year survival rates of these two groups were 33.3% and 15.1%, respectively. Using the eighth staging system, the median survival periods of patients classified as N0, N1, and N2 were 31.5, 18.6, and 16.2 months, respectively, differing significantly between the N0 and N1 groups (p＜0.001) and significantly but marginally between the N1 and N2 groups (p=0.042; Fig. 2 ). The 5 year overall survival rates of patients in the N0, N1, and N2 groups were 33.3%, 16.1%, and 11.0%, respectively. To reduce any bias associated with T stage, we compared survival rates between the N stages after T stage was fixed.
We identified 757 patients as T2 stage using the eighth AJCC staging system; those with N0 and N1 according to the seventh staging system had median survival periods When N stage in these 757 patients was classified according to the eighth staging system, those classified as N0, N1, and N2 had median survival periods of 32.3, 18.9, and 16.8 months, respectively, with statistically significant differences between the N0 and N1 (p＜0.001) and between the N1 and N2 (p=0.027) groups (Fig. 2) . Moreover, the 5 year overall survival rates of patients in the N0, N1, and N2 groups were 31.5%, 16.4%, and 9.1%, respectively. 
Analysis of prognostic factors
Multivariate analysis of factors associated with overall survival was performed in all patients (Table 4) Proposal for upgrading the staging system Although the eighth staging system showed a more even distribution of stages than the seventh staging system, the former had several limitations. First, the p-values between each pair of T stages were marginal. Second, the difference in median survival between the N1 and N2 groups was only 2 months. Overall survival of the 1169 patients was reanalyzed based on tumor size (Table 5) .
Because median tumor size was 3 cm, it was used as a cutoff, with the mean survival differing significantly in patients with tumors ＜3 cm and ≥3 cm in diameter (p＜0.001). Survival, however, varied greatly in patients with tumors ＞6 cm. We therefore classified the T1 and PD/PPPD, pancreaticoduodenectomy/pylorus-preserving pancreaticoduodenectomy; DPS, distal pancreatectomy with splenectomy; TPS, total pancreatectomy with splenectomy; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CTx, chemotherapy; CRTx, chemoradiotherapy T2 groups based on tumor size ＜3 cm and ≥3 cm.
When survival was analyzed based on the number of metastatic lymph nodes, we found the only difference between patients having 0 and ≥1 metastatic nodes (p＜0.001; Table 6 ). Therefore, we suggest categorizing N stage as N0 and N1, as in the seventh AJCC staging system.
Analysis of overall survival using this T and N staging system yielded three significantly different groups, with group 1 being those staged as T1N0, group 2 being those staged as T2N0 and T1N1, and group 3 being those staged as T2N1 (Fig. 4) . Comparisons showed statistically significant differences between patients staged as T1N0 and T2N0 (p＜0.001) and T1N1 and T2N1 (p＜0.001), but not between those staged as T2N0 and T1N1 (p=0.207). By contrast, when the eighth staging system was used, all pairwise comparisons of stages were statistically significant.
In contrast to the seventh staging system, the eighth staging system classifies T stage mainly by tumor size, regardless of tumor extent. Thus, we reanalyzed our data by tumor size, with 3 cm representing the median size.
Overall survival differed significantly in patients with tumors ＜3 cm (classified as T1) and ≥3 cm (classified as T2) in size. Although the eighth staging system classified N stage into three groups, based on the number of metastatic lymph nodes, reanalysis of our data showed that the only difference in survival was between patients with 0 and ≥1 metastatic lymph nodes, suggesting that N stage should be classified as N0 and N1, as in the seventh staging system. Analysis of overall survival using this modified T and N staging system yielded three significantly different groups, consisting of patients classified as T1N0
(group 1), T2N0 and T1N1 (group 2), and T2N1 (group 3). This grouping system was a better predictor of overall survival than the eighth AJCC staging system. This study had several limitations, including its analysis of patients from a single center, which may have introduced a selection bias. However, because surgical and therapeutic methods were standardized, the data from our center were consistent with those from other centers.
In conclusion, the eighth AJCC staging system showed a more even distribution of tumor stages than the seventh AJCC staging system. However, some differences were marginal, and this new staging system was not an effective predictor of overall survival. Efforts are needed to upgrade the PDAC staging system, as shown by our use of tumor size (＜3 cm vs. ≥3 cm) and number of metastatic lymph nodes (0 vs. ≥1). Data from multiple institutions are required to validate our staging system.
